Regeneron Acquires 23andMe Assets for $256 Million

An update from 23andMe Holding ( (MEHCQ) ) is now available.

On March 23, 2025, 23andMe filed for Chapter 11 bankruptcy and conducted an auction for its assets, concluding on May 16, 2025. Regeneron Pharmaceuticals was selected as the successful bidder, agreeing to acquire substantially all of 23andMe’s assets for $256 million. The transaction, subject to court approval, includes commitments to maintain 23andMe’s privacy policies and offer employment to its employees. The sale is part of 23andMe’s restructuring efforts under bankruptcy proceedings, with a court hearing scheduled for June 17, 2025.

The most recent analyst rating on (MEHCQ) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on 23andMe Holding stock, see the MEHCQ Stock Forecast page.

Spark’s Take on MEHCQ Stock

According to Spark, TipRanks’ AI Analyst, MEHCQ is a Neutral.

23andMe Holding’s overall stock performance is weak, primarily due to significant financial challenges, including declining revenues and persistent net losses. The technical analysis also suggests a bearish trend with no strong momentum to reverse it. The negative valuation metrics further highlight the company’s struggles with profitability. Improvements in financial performance and strategic adjustments to reverse negative trends are critical for enhancing investor confidence.

To see Spark’s full report on MEHCQ stock, click here.

More about 23andMe Holding

23andMe is a genetics-led consumer healthcare and biotechnology company focused on empowering a healthier future through its genetic testing services. It offers products such as the Personal Genome Service, Total Health, and Research Services. The company is known for its consumer genome services and has a market focus on providing health insights through genetic data.

Average Trading Volume: 4,083,177

Technical Sentiment Signal: Sell

Current Market Cap: $24.14M

Learn more about MEHCQ stock on TipRanks’ Stock Analysis page.